Home Newsfeeds Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Goldman Sachs analyst Corinne Jenkins initiates coverage on Altimmune (NASDAQ:ALT) with a Buy rating and announces Price Target of $20.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Goldman Sachs analyst Corinne Jenkins initiates coverage on Altimmune (NASDAQ:ALT) with a Buy rating and announces Price Target of $20.

Analyst Ratings

Assessing Cintas: Insights From 7 Financial Analysts

By Benzinga Insights

January 25, 2:00 PM

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Cintas (NASDAQ:CTAS)…

CTAS

Gucci’s Revival Boost: Kering Reportedly Taps Stefano Cantino as Label’s Deputy CEO

By Shivani Kumaresan

April 11, 9:33 AM

Kering elevates Cantino to Deputy CEO of Gucci, aiming for brand revival. Set to commence on May 2, Cantino will collaborate with Palus to redefine Gucci's strategy.

PPRUF

Insights Into Amgen’s Performance Versus Peers In Biotechnology Sector

By Benzinga Insights

December 11, 12:00 PM

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry…

AMGN

Top 5 Consumer Stocks That Could Lead To Your Biggest Gains This Month

By Avi Kapoor

December 12, 7:46 AM

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.

CJET

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Related Posts

Assessing Cintas: Insights From 7 Financial Analysts

Gucci’s Revival Boost: Kering Reportedly Taps Stefano Cantino as Label’s Deputy CEO

Insights Into Amgen’s Performance Versus Peers In Biotechnology Sector

Top 5 Consumer Stocks That Could Lead To Your Biggest Gains This Month